Nykode Therapeutics AS 2022 SR
The report is Nykode Therapeutics' inaugural ESG report for 2022, detailing the company's commitment to sustainability and its baseline environmental and social performance. The company established its first measures for greenhouse gas emissions, reporting 745 tonnes of CO2e (market-based), and total waste of 3.734 tonnes. Social highlights include a workforce of 155 employees with 67% female representation and a board and senior management team that is 38% female. The report follows SASB Biotechnology & Pharmaceuticals standards and references GRI for materiality, while also addressing compliance with the Norwegian Transparency Act.
Company: Nykode Therapeutics AS
Sector: Professional & technical services
Country: Norway
Year: 2022
Type: SR
Pages: 15
Back to company
Nykode Therapeutics AS
ESG Report
The report is Nykode Therapeutics' inaugural ESG report for 2022, detailing the company's commitment to sustainability and its baseline environmental and social performance. The company established its first measures for greenhouse gas emissions, reporting 745 tonnes of CO2e (market-based), and total waste of 3.734 tonnes. Social highlights include a workforce of 155 employees with 67% female representation and a board and senior management team that is 38% female. The report follows SASB Biotechnology & Pharmaceuticals standards and references GRI for materiality, while also addressing compliance with the Norwegian Transparency Act.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Apr 1, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees